Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P08579
UPID:
RU2B_HUMAN
Alternative names:
-
Alternative UPACC:
P08579; B2R7J3; D3DW21; Q9UJD4
Background:
The U2 small nuclear ribonucleoprotein B'', a pivotal component of the spliceosome, plays a crucial role in pre-mRNA splicing. It is intricately associated with sn-RNP U2, enhancing the binding of stem loop IV of U2 snRNA. This protein's involvement in the splicing process underscores its importance in the post-transcriptional regulation of gene expression.
Therapeutic significance:
Understanding the role of U2 small nuclear ribonucleoprotein B'' could open doors to potential therapeutic strategies. Its critical function in mRNA splicing presents a unique opportunity for the development of novel treatments targeting genetic disorders.